I
István Bitter
Researcher at Semmelweis University
Publications - 269
Citations - 12420
István Bitter is an academic researcher from Semmelweis University. The author has contributed to research in topics: Schizophrenia (object-oriented programming) & Olanzapine. The author has an hindex of 42, co-authored 254 publications receiving 10719 citations. Previous affiliations of István Bitter include Eli Lilly and Company & New York University.
Papers
More filters
Journal ArticleDOI
Genome-wide association study identifies five new schizophrenia loci
Stephan Ripke,Alan R. Sanders,Kenneth S. Kendler,Douglas F. Levinson,Pamela Sklar,Pamela Sklar,Peter Holmans,Danyu Lin,Jubao Duan,Roel A. Ophoff,Roel A. Ophoff,Ole A. Andreassen,Edward M. Scolnick,Sven Cichon,David St Clair,Aiden Corvin,Hugh Gurling,Thomas Werge,Dan Rujescu,Douglas Blackwood,Carlos N. Pato,Anil K. Malhotra,Anil K. Malhotra,Shaun Purcell,Frank Dudbridge,Benjamin M. Neale,Lizzy Rossin,Peter M. Visscher,Danielle Posthuma,Douglas M. Ruderfer,Ayman H. Fanous,Ayman H. Fanous,Ayman H. Fanous,Hreinn Stefansson,Stacy Steinberg,Bryan J. Mowry,Vera Golimbet,Marc De Hert,Erik G. Jönsson,István Bitter,Olli Pietiläinen,David A. Collier,Sarah Tosato,Ingrid Agartz,Margot Albus,Madeline Alexander,Richard Amdur,Richard Amdur,Farooq Amin,Farooq Amin,Nicholas Bass,Sarah E. Bergen,Donald W. Black,Anders D. Børglum,Matthew A. Brown,Richard Bruggeman,Nancy G. Buccola,William Byerley,Wiepke Cahn,Rita M. Cantor,Vaughan J. Carr,Stanley V. Catts,Khalid Choudhury,C. Robert Cloninger,Paul Cormican,Nicholas John Craddock,Patrick Danoy,Susmita Datta,Lieuwe de Haan,Ditte Demontis,Dimitris Dikeos,Srdjan Djurovic,Peter Donnelly,Gary Donohoe,L. Duong,Sarah Dwyer,Anders Fink-Jensen,Robert Freedman,Nelson B. Freimer,Marion Friedl,Lyudmila Georgieva,Ina Giegling,Michael Gill,Birte Glenthøj,Stephanie Godard,Marian L. Hamshere,Mark Hansen,Thomas Hansen,Annette M. Hartmann,Frans Henskens,David M. Hougaard,Christina M. Hultman,Andres Ingason,Assen Jablensky,Klaus D. Jakobsen,M. Jay,Gesche Jürgens,René S. Kahn,Matthew C. Keller,Gunter Kenis,Elaine Kenny,Yunjung Kim,George Kirov,H. Konnerth,Bettina Konte,Lydia Krabbendam,Robert Krasucki,Virginia K. Lasseter,Claudine Laurent,Jacob Lawrence,Todd Lencz,Todd Lencz,F. Bernard Lerer,Kung Yee Liang,Paul Lichtenstein,Jeffrey A. Lieberman,Don H. Linszen,Jouko Lönnqvist,Carmel M. Loughland,Alan W Maclean,Brion S. Maher,Wolfgang Maier,J. Mallet,P. Malloy,Manuel Mattheisen,Morten Mattingsdal,Kevin A. McGhee,John J. McGrath,Andrew M. McIntosh,Duncan E. McLean,Andrew McQuillin,Ingrid Melle,Patricia T. Michie,Vihra Milanova,Derek W. Morris,Ole Mors,Preben Bo Mortensen,Valentina Moskvina,Pierandrea Muglia,Inez Myin-Germeys,Deborah A. Nertney,Gerald Nestadt,Jimmi Nielsen,Ivan Nikolov,Merete Nordentoft,Nadine Norton,Markus M. Nöthen,Colm O'Dushlaine,Ann Olincy,Line Olsen,F. Anthony O'Neill,Torben F. Ørntoft,Michael John Owen,Christos Pantelis,George N. Papadimitriou,Michele T. Pato,Leena Peltonen,Leena Peltonen,Hannes Petursson,Ben S. Pickard,Jonathan Pimm,Ann E. Pulver,Vinay Puri,Digby Quested,Emma M. Quinn,Henrik B. Rasmussen,János Réthelyi,R. Ribble,Marcella Rietschel,Marcella Rietschel,Brien P. Riley,Mirella Ruggeri,Ulrich Schall,Thomas G. Schulze,Thomas G. Schulze,Sibylle G. Schwab,Sibylle G. Schwab,Rodney J. Scott,Jianxin Shi,Engilbert Sigurdsson,Jeremy M. Silverman,Jeremy M. Silverman,Chris C. A. Spencer,Kari Stefansson,Amy Strange,Eric Strengman,T. Scott Stroup,Jaana Suvisaari,Lars Terenius,Srinivasa Thirumalai,Johan H. Thygesen,Sally Timm,Draga Toncheva,Edwin J. C. G. van den Oord,Jim van Os,Ruud van Winkel,Ruud van Winkel,Jan H. Veldink,Dermot Walsh,August G. Wang,Durk Wiersma,Dieter B. Wildenauer,Hywel Williams,Nigel Williams,Brandon Wormley,Stan Zammit,Patrick F. Sullivan,Patrick F. Sullivan,Michael Conlon O'Donovan,Mark J. Daly,Pablo V. Gejman +210 more
TL;DR: The authors examined the role of common genetic variation in schizophrenia in a genome-wide association study of substantial size: a stage 1 discovery sample of 21,856 individuals of European ancestry and a stage 2 replication sample of 29,839 independent subjects.
Journal ArticleDOI
Common variants conferring risk of schizophrenia
Hreinn Stefansson,Hreinn Stefansson,Roel A. Ophoff,Roel A. Ophoff,Roel A. Ophoff,Stacy Steinberg,Stacy Steinberg,Ole A. Andreassen,Sven Cichon,Dan Rujescu,Thomas Werge,Olli Pietilainen,Ole Mors,Preben Bo Mortensen,Engilbert Sigurdsson,Omar Gustafsson,Mette Nyegaard,Annamari Tuulio-Henriksson,Andres Ingason,Thomas Hansen,Jaana Suvisaari,Jouko Lönnqvist,Tiina Paunio,Anders D. Børglum,Anders D. Børglum,Annette M. Hartmann,Anders Fink-Jensen,Merete Nordentoft,David M. Hougaard,Bent Nørgaard-Pedersen,Yvonne Böttcher,Jes Olesen,René Breuer,Hans-Jürgen Möller,Ina Giegling,Henrik B. Rasmussen,Sally Timm,Manuel Mattheisen,István Bitter,János Réthelyi,Brynja B. Magnusdottir,Thordur Sigmundsson,Pall I. Olason,Gisli Masson,Jeffrey R. Gulcher,Magnús Haraldsson,Ragnheidur Fossdal,Thorgeir E. Thorgeirsson,Unnur Thorsteinsdottir,Unnur Thorsteinsdottir,Mirella Ruggeri,Sarah Tosato,Barbara Franke,Eric Strengman,Lambertus A. Kiemeney,Ingrid Melle,Srdjan Djurovic,Lilia I. Abramova,Kaleda Vg,Julio Sanjuán,Rosa de Frutos,Elvira Bramon,Evangelos Vassos,Gillian Fraser,Ulrich Ettinger,Marco Picchioni,Nicholas Walker,T. Toulopoulou,Anna C. Need,Dongliang Ge,Joeng Lim Yoon,Kevin V. Shianna,Nelson B. Freimer,Rita M. Cantor,Robin M. Murray,Augustine Kong,Vera Golimbet,Angel Carracedo,Celso Arango,Javier Costas,Erik G. Jönsson,Lars Terenius,Ingrid Agartz,Hannes Petursson,Markus M. Nöthen,Marcella Rietschel,Paul M. Matthews,Pierandrea Muglia,Leena Peltonen,David St Clair,David Goldstein,Kari Stefansson,Kari Stefansson,David A. Collier,David A. Collier +94 more
TL;DR: Findings implicating the MHC region are consistent with an immune component to schizophrenia risk, whereas the association with NRGN and TCF4 points to perturbation of pathways involved in brain development, memory and cognition.
Journal ArticleDOI
Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis.
TL;DR: Prevalence of ADHD in adults declines with age in the general population and the unclear validity of DSM–IV diagnostic criteria for this condition can lead to reduced prevalence rates by underestimation of the prevalence of adult ADHD.
Journal ArticleDOI
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).
Herbert Y. Meltzer,Larry Alphs,Alan I. Green,A. Carlo Altamura,Ravi Anand,Alberto Bertoldi,Marc Bourgeois,Guy Chouinard,M. Zahur Islam,John M. Kane,Ranga Krishnan,Jean-Pierre Lindenmayer,Steven G. Potkin,Saide Altinsan,Siemion Altman,Likiana Avigo,Richard Balon,Vanda Benešová,Luis Bengochea,István Bitter,Elisabeth Bokowska,Bernardo Carpiniello,Daniel E. Casey,Giovanni B. Cassano,James C.-Y. Chou,Libor Chvila,Jean Dalery,Pedro L. Delgado,Liliana Dell'Osso,Carl Eisdorfer,Robin Emsley,Dawn Eng,Tom A. Fahy,Vera Folnegovic,Sophie Frangou,Pedro Gargoloff,Alberto Giannelli,Ira D. Glick,Richard Greenberg,George T. Grossberg,Doris Gundersen,Hannale Heila,George Hsu,Naveed Iqbal,Miro Jakovljević,Richard C. Josiassen,Akos Kassaifarkas,Robert Kerwin,Frederic Khidichian,Mary Ann Knesevich,Jack S. Krasuski,Vinod Kumar,Veronica W. Larach,Michael D. Lesem,Shôn Lewis,Pierre-Michel Llorca,H. Edward Logue,Stephen Martin,Muriel Maurel-Raymondet,Laszlo Mod,Eva Morik,Carlos Morra,Ann M. Mortimer,Mojtaba Noursalehi,Gyorgy Ostorharics-Horvath,Ivo Paclt,Jörg Pahl,Linda Pestreich,J. L. Peters,Rosario Pioli,Michael G. Plopper,Thomas Posever,Mark Hyman Rapaport,Delbert Robinson,Carlo Andrea Robotti,Harry Rohme,Frédéric Rouillon,David A. Sack,Isaac Sakinsofsky,Phillip Seibel,George M. Simpson,Nancy Temkin,Oladapo Tomori,Santha Vaidain,Zdeòka Vyhnándová,Frederick Young,Daniel L. Zimbroff,Marie Agathe Zimmerman +87 more
TL;DR: It is suggested that clozapine therapy significantly reduces suicidal behavior in patients with schizophrenia and schizoaffective disorder at high risk for suicide, and use of clozAPine in this population should lead to a significant reduction in suicidal behavior.
Journal ArticleDOI
Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial
Michael J. Detke,Curtis Wiltse,Craig H. Mallinckrodt,Robert K. McNamara,Mark A. Demitrack,István Bitter +5 more
TL;DR: These data support previous findings that duloxetine is safe, efficacious, and well tolerated in the acute treatment of major depressive disorder.